Atlas Trials

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Clinical trial NCT04231877 · RECRUITING

Trial details

NCT number
NCT04231877
Sponsor
University of Washington
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaT-Cell/Histiocyte-Rich Large B-Cell LymphomaGray-Zone Lymphoma
Start date
2020-10-27
Primary completion
2026-12-01
Enrollment
56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.